Iktos vs Insilico Medicine (2026)
Both sell AI drug discovery software as well as running discovery work. Iktos offers Makya for generative design with synthetic accessibility built in, Spaya for retrosynthesis, robotic synthesis and testing, and engine APIs that connect to a team's own workflows. Insilico Medicine, listed in Hong Kong, licenses its Pharma.AI suite, with PandaOmics for targets, Chemistry42 for generative chemistry and inClinico for trial outcome prediction, offers a PandaOmics Box for local deployment, and develops clinical programs of its own. Iktos concentrates on chemistry and synthesis; Insilico covers more of the chain, from target to trial.
- Generative design as software, Makya, with synthesis built into generation.
- Retrosynthesis with Spaya, routing to commercially available starting materials.
- Robotic synthesis, purification and testing, and APIs that plug the models into a team's own workflows.
- Software a team can license across the discovery chain, from target identification to generative chemistry and trial outcome prediction.
- Local deployment through the PandaOmics Box, and client work under an ISO 27001 certified security management system.
- Its own clinical programs developed on the same suite.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Iktos and Insilico Medicine are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Iktos | Insilico Medicine |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2016 | 2014 |
| Headquarters | Paris, France | Cambridge, Massachusetts |
| Website | iktos.ai | insilico.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Insilico Medicine
-
Clinical evidence
Insilico posted a medRxiv preprint on the models that score clinical trials in its inClinico platform, trained only on what was known when each trial was registered.
Source -
Product / capability
Insilico announced that Model Context Protocol servers are now available across its Pharma.AI software, so outside AI agents can connect directly to its biology, chemistry and biologics engines, including Generative Biologics, PandaOmics and Chemistry42, and run multistep discovery workflows.
Source -
Model / architecture
Insilico released a set of small language models trained as scientific specialists for chemistry and biology through its MMAI Gym for Science framework.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Iktos is a Paris generative AI and robotics company for small molecule drug discovery, founded in 2016. It sells two AI platforms: Makya, a generative design SaaS trained on millions of reactions that builds synthetic accessibility and a target product profile into generation (Makya 2.0 added a new analysis interface, and new ligand based 3D generative models arrived in January 2026), and Spaya, an AI retrosynthesis platform that finds routes to commercially available starting materials.
Source: AI Health Index, September 2026
Insilico Medicine is a generative AI drug discovery company (HKEX: 3696), headquartered in Cambridge, Massachusetts with operations in Hong Kong, Abu Dhabi and Shanghai, that both licenses software and develops its own medicines.
Source: AI Health Index, September 2026
Questions buyers ask
How do Iktos and Insilico Medicine work with the EHR?
The integration Iktos describes is generic: Makya accepts a project's own data and connects external models and scoring functions through an API, can be driven as a Python package, and Iktos has announced engine APIs for agentic workflows and computational chemistry pipelines; Spaya is said to integrate with various data providers.
Insilico describes a generic integration path: the suite runs on the client's preferred cloud (AWS, Azure or others as specified), a PandaOmics Box is offered for local deployment, and the company has published work on connecting its tools to other software through standard model context interfaces. The electronic lab notebook Insilico describes among its security controls is an internal system. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How are Iktos and Insilico Medicine priced and sold?
Makya and Spaya are licensable software, with a demo request as the route in, and Iktos also runs discovery collaborations and its own pipeline; a strategic collaboration with Servier was reported at a potential value above €1 billion, which describes one negotiated deal rather than a price.
Each product page routes to a request form, a PandaOmics Box is offered alongside the hosted products, and as a listed company Insilico reports its own financial results, which show its revenue rather than a customer's cost. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do Iktos and Insilico Medicine handle patient data?
With Iktos, no patient data is in the workflow.
In Insilico Medicine's case, the company's published privacy policy (effective October 30, 2020) covers the company website rather than the software. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Which settings and specialties do Iktos and Insilico Medicine cover?
For Iktos, the products and pipeline cover small molecule design and synthesis planning, with robotics biology for protein protein and RNA protein interactions, molecular glues and PROTACs, and in house programs in inflammation and autoimmune disease (MTHFD2) and obesity (amylin receptor).
With Insilico Medicine, results sit where the programs have run: a fibrosis candidate in Phase III, thirteen programs cleared for IND, and published work behind them. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers.
Both records were reviewed on this site in September 2026. Neither publishes prices, and part of Iktos's published material could not be read for this review.
Ask both how their generative models handle synthesis feasibility before a chemist sees a design.